According to Sanyuan Biotech's announcement, the company has been identified as a qualified investor in the capital increase project of Sinoma Artificial Crystal Research Institute Co., Ltd., and plans to increase its capital with its own capital of 30 million yuan, subscribe for an additional registered capital of 7.692.37 million yuan. After the transaction is completed, it will hold 4.8844% of the shares in the target company. This investment is a matter within management's approval authority. It does not constitute a related transaction or major asset restructuring. It still needs to be registered for industrial and commercial changes, and there is some uncertainty.

According to Sanyuan Biotech's announcement, the company has been identified as a qualified investor in the capital increase project of Sinoma Artificial Crystal Research Institute Co., Ltd., and plans to increase its capital with its own capital of 30 million yuan, subscribe for an additional registered capital of 7.692.37 million yuan. After the transaction is completed, it will hold 4.8844% of the shares in the target company. This investment is a matter within management's approval authority. It does not constitute a related transaction or major asset restructuring. It still needs to be registered for industrial and commercial changes, and there is some uncertainty.